Importance The chronic receipt of angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin receptor blockers (ARBs) has been assumed to exacerbate complications …

Renin–angiotensin–aldosterone system (RAAS) inhibitors, including angiotensin‐converting
enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are one of the most …

Background and rationale Some studies of hospitalized patients suggested that the risk of
death and/or severe illness due to COVID-19 is not associated with the use of angiotensin …

This is the largest meta-analysis including critical events and mortality data on patients
prescribed ACEi/ARB and found evidence of beneficial effects of chronic ACEi/ARB use …

Aims: We sought to evaluate the association of angiotensin-converting-enzyme inhibitors
(ACEI) or AT1 blockers (ARB) therapy with clinical outcomes in patients with coronavirus …

The coronavirus disease 2019 (COVID-19) is caused by the infection of severe acute
respiratory syndrome coronavirus 2, having gradually developed into a pandemic and …

Introduction Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor
blockers (ARBs) share their target receptor site with the SARS-CoV-2 virus, that may cause …

Introduction The use of renin-angiotensin system (RAS) inhibitors, including angiotensin-
converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), was …

Aims This meta-analysis provides summary odds ratio (OR) estimates for associations
between treatment with (vs. without) renin–angiotensin system blockers and risk of severe …

Abstract Background and Aims; To investigate the association between use of angiotensin-
converting enzyme inhibitor (ACEI)/angiotensin-receptor blocker (ARB) and outcomes of …